Cardiac-valve prosthesis

Abstract
A cardiac-valve prosthesis which can be used, for example, as a valve for percutaneous implantation. The prosthesis includes an armature for anchorage of the valve prosthesis in the implantation site. The armature defines a lumen for passage of the blood flow and supports a set of prosthetic valve leaflets, which, under the action of the blood flow, are able to move into a radially divaricated condition to enable the flow of the blood through the lumen in a first direction and a radially contracted condition, in which the valve leaflets co-operate with one another and block the flow of the blood through the prosthesis in the opposite direction. The armature includes, in one embodiment, two annular elements connected by anchor members having the capacity of projecting radially with respect to the prosthesis, and support members for the set of leaflets, the support members being carried by at least one of the annular elements so as to leave substantially disengaged the aforesaid lumen for passage of the blood.
Description
CROSS REFERENCE TO RELATED APPLICATION

This application is related to co-pending U.S. patent application Ser. No. 11/066,346 entitled “Minimally-Invasive Cardiac-Valve Prosthesis,” and claims priority from Italian patent application number TO2005/A000074, filed on Feb. 10, 2005. Each of the above-identified applications is hereby incorporated by reference for all purposes.


TECHNICAL FIELD

The present invention relates to cardiac-valve prostheses. More specifically, the present invention is directed to a prosthesis that is amenable to a minimally-invasive implantation.


BACKGROUND

Recently, there has been increasing consideration given to the possibility of using, as an alternative to traditional cardiac-valve prostheses, valves designed to be implanted using minimally-invasive surgical techniques or endovascular delivery (the so-called “percutaneous valves”). Implantation of a percutaneous valve (or implantation using thoracic-microsurgery techniques) is a far less invasive act than the surgical operation required for implanting traditional cardiac-valve prostheses. Further details of exemplary percutaneous implantation techniques are provided in U.S. Publication 2002/0042651, U.S. Pat. No. 3,671,979, and U.S. Pat. No. 5,954,766, which are hereby incorporated by reference.


These prosthetic valves typically include an anchoring structure, which is able to support and fix the valve prosthesis in the implantation position, and prosthetic valve elements, generally in the form of leaflets or flaps, which are stably connected to the anchoring structure and are able to regulate blood flow.


Furthermore, the methods of implantation of valves via a percutaneous route or by means of thoracic microsurgery are very frequently irrespective of the effective removal of the natural valve leaflets. Instead, the cardiac valve may be introduced in a position corresponding to the natural annulus and deployed in situ by simply divaricating definitively the natural valve leaflets.


There is a need for a percutaneous valve that does not run the risk of being displaced (dislodged) with respect to the implantation position, as a result of the hydraulic thrust exerted by the blood flow. There is a further need for a percutaneous valve that secures tightly to the flow duct generally defined by the natural valve annulus, such that it resists blood flow around the outside of the percutaneous valve structure.


SUMMARY

In an exemplary embodiment, a cardiac valve prosthesis according to the invention is made so that the entire armature of the valve, or at least the anchorage parts, adhere to the native walls of the implantation site, without interfering with the blood flow, which thus remains practically free. In a preferred way, the anchorage portions moreover have appropriate slits that prevent their interference with the coronary ostia. The anchorage portions and the portions of functional support of the armature can constitute either different parts of a single structure or parts that are structurally distinct from one another. Super-elastic materials can be used in order to obtain a structure that is able to be collapsed for advancement to its implantation site, and to self-recover its expanded geometry once the prosthesis is deployed in the implantation position. The entire armature of the valve, or at least the anchorage parts, can be made even of re-absorbable material, whereas the valve leaflets can be made of biological and/or synthetic tissues, in part colonizable or re-absorbable. In this way, it is possible to obtain anchorage of the device during the period necessary for integration of the valve prosthesis with the physiological tissues of the anatomical site of implantation. Subsequently, there is dissolution of the artificial structure that enables initial anchorage. Amongst the various advantages linked to this solution to be emphasized is the creation of the ideal conditions for a possible prosthetic re-implantation. The armature can include anchorage formations or portions of the supporting structure of the valve flaps made at least partially of shape-memory material (e.g., Nitinol) that enable creation or regulation of the anchorage, i.e., regulation of the modalities and the magnitude of splaying-out of the valve leaflets through control of the memory of the shape-memory material (e.g., by controlling its temperature), according to a mechanism similar to what is described in the document No. EP-A-1 088 529.


While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. As will be realized, the invention is capable of modifications in various obvious aspects, all without departing from the spirit and scope of the present invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described, purely by way of non-limiting example, with reference to the annexed plate of drawings, in which:



FIG. 1 is a general perspective view of a cardiac-valve prosthesis according to one embodiment of the present invention;



FIGS. 2 to 7 illustrate different embodiments of an armature portion of the cardiac valve prosthesis according to the present invention;



FIGS. 8 and 9 illustrate plan and cross-sectional views, respectively, of the cardiac valve prosthesis implanted at an implantation site in a patient, according to an embodiment of the present invention; and



FIG. 10 is a schematic cross-sectional view of an implantation site for the cardiac valve prosthesis according to one embodiment of the present invention.





While the invention is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.


DETAILED DESCRIPTION

In the figures of the annexed plate of drawings, the reference number 1 designates as a whole a cardiac-valve prosthesis, which can be implanted percutaneously or resorting to techniques of thoracic microsurgery, or else of implantation of a “sutureless” type. Essentially, the prosthesis 1 represented in FIG. 1 includes an armature 2, having the characteristics that emerge more clearly from the representation of FIGS. 2 to 7, and a valve sleeve 3 coupled to the armature 2 and including three valve leaflets 3a, 3b, 3c.


As illustrated in FIG. 2, the armature 2 of the prosthesis 1 can have a general cage-like structure, with a general symmetry of a cylindrical type about a principal axis X1. In percutaneous valves the axis X1 is designed to correspond usually to the principal axis of the distal part of the catheter used for implantation of the prosthesis 1. For the present purpose, the axis X1 can be viewed basically as an entity of a purely geometrical nature. As shown, the armature 2 defines a lumen which operates as a flow tube or duct to accommodate the flow of blood there through. As will be readily apparent to those skilled in the art, a major characteristic of the present invention is the absence of structural elements that can extend in the lumen through which blood flows.


The valve sleeve 3 may be constructed according to various techniques known in the art. For example, techniques for the formation of the valve leaflets, assembly of the valve sleeve and installation thereof on an armature that can be used in the context of the present invention are described in EP-A-0 133 420, EP-A-0 155 245 and EP-A-0 515 324 (all of which are hereby incorporated by reference), the latter document referring to the construction of a cardiac-valve prosthesis of biological tissue of the type commonly referred to as “stentless.”


As further illustrated, the valve sleeve 3 includes a base portion 30 with an overall annular pattern, designed to extend from the lower portion of the prosthesis 1, which, in the implantation site, is in a position proximal with respect to the direction of flow of the blood through the prosthesis (from below upwards, as viewed in FIG. 1). Starting from the base portion 30, there extend in an axial direction towards the inside of the structure of the prosthesis 1 three pleat formations 32. The valve leaflets 3a, 3b and 3c extend like a festoon, with a general claw-like conformation, between pairs of pleat formations 32 adjacent to one another.


As illustrated in FIG. 1, each valve leaflet 3a, 3b and 3c has a fluidodynamically proximal edge with an arched pattern, which extends from the base formation 30 and along two adjacent pleat formations 32, and a fluidodynamically distal edge, which extends towards the central orifice of the prosthesis so as to be able to co-operate with the homologous edges of the other valve leaflets. The terms “fluidodynamically proximal” and “fluidodynamically distal” refer to the direction of free flow of the blood through the prosthesis, a direction that is from below upwards, as viewed in the figures of the annexed plate of drawings.


As will be understood by those of ordinary skill in the art, in operation, the valve leaflets 3a, 3b, 3c are able to undergo deformation, divaricating and moving up against the armature 2 so as to enable free flow of the blood through the prosthesis. When the pressure gradient, and hence the direction of flow, of the blood through the prosthesis tends to be reversed, the valve leaflets 3a, 3b, 3c then move into the position represented in FIG. 1, in which they substantially prevent the flow of the blood through the prosthesis. Usually, the valve leaflets 3a, 3b, 3c are made in such a way as to assume spontaneously, in the absence of external stresses, the closed configuration represented in FIG. 1.



FIGS. 2 through 7 depict the armature 2 according to various embodiments of the present invention. Referring first to FIG. 2, it is shown that the armature 2 (which may be made of metal material, such as for example the material commonly referred to as Nitinol) includes two annular elements 20a, 20b, which generally occupy respective end positions within the armature 2. In one embodiment, in the site of implantation of the prosthesis 1, the annular elements 20a and 20b are designed to be located, respectively, upstream and downstream of the sinuses of Valsalva.


During implantation, the prosthesis 1 is advanced towards the implantation site in a radially contracted configuration, with the annular elements 20a and 20b in a radially collapsed configuration. In one embodiment, when so collapsed, the annular elements 20a, 20b have a minimum diameter of about 5 to about 15 mm, according to the technique of implantation for which the prosthesis is designed. Once the prosthesis 1 has reached the implantation site, the annular elements 20a, 20b are made/allowed to expand until they reach their normal expanded configuration, with a diameter that ranges, in one embodiment, from about 18 to about 30 mm.


In order to enable the movement of expansion, the annular elements 20a and 20b are made, according to the illustrated embodiment, with a mesh structure substantially resembling the mesh structure of a stent for angioplasty. It will be appreciated in fact that the annular elements 20a and 20b are designed to perform a movement of radial expansion (with subsequent maintenance of the radially expanded configuration) substantially resembling the movement of expansion in situ of an angioplasty stent.


In the example of embodiment illustrated herein, the annular elements 20a and 20b have a rhomboidal-mesh structure. In other embodiments, the parts 20a, 20b can be made with any structure that is able to ensure the necessary functionality.


In one embodiment, as shown in FIG. 2, the annular element 20a designed to be located in a position proximal with respect to the flow of the blood through the prosthesis 1 (i.e., on the inflow side of the blood in the prosthesis 1 in the conditions of free flow) may have a proximal end that is at least slightly flared outward like an enlarged opening of the flow duct of the blood. This configuration functions to promote a more positive anchorage of the annular element 20a, and in turn, the prosthesis 1, to the valve annulus, thus promoting the perivalvar tightness, improving the haemodynamics, and adapting (i.e., radiusing) the lines of blood flow in the ventricular chamber to the flow tube constituted by the valve sleeve.


As shown, the annular elements 20a, 20b are connected to one another by anchor members 22, which in the illustrated embodiment, are generally arched, projecting towards the outside of the prosthesis 1. In one embodiment, the anchor members 22 are designed such that when the prosthesis 1 is positioned at the implantation site, the anchor members 22 can extend on the outside of the sinuses of Valsalva so as to ensure firm anchorage in situ of the prosthesis 1.


With the prosthesis 1 in the radially contracted configuration adopted for implantation, the anchor members 22 are normally maintained in a position (not shown) recalled towards the central axis X1 of the prosthesis 1. This can occur, for example, via a retention means such as a tubular sheath of an implantation catheter through which the radially contracted prosthesis is advanced. Subsequently, once disengaged from the retention means, the anchor members 22 may assume the arched pattern represented in the figures so as to be able to project (protrude), in one embodiment, within the sinuses of Valsalva.


As will be appreciated by those skilled in the art, the sinuses of Valsalva are, in a normal heart, three in number, and are distributed in an approximately angularly uniform way around the root of the artery distal to the semilunar valve (i.e., the aortic or pulmonary valve). Accordingly, as illustrated, the prosthesis 1 may include three anchor members 22 (or three groups of anchor members) set at an angular distance apart of about 120° with respect to the central axis X1 of the prosthesis.


In the exemplary embodiment illustrated, the anchor members 22 are made in the form of ribbon-like elements that extend in a generally sinusoidal or serpentine path, with bends or open loops situated on either side with respect to an ideal line extending approximately in the direction of the generatrices of the overall cylindrical shape of the prosthesis. In another embodiment of the invention, the sinusoidal pattern can be obtained with bends or open loops that extend from one side and from the other with respect to a line that extends in a circumferential direction with respect to the prosthesis. In yet another embodiment, the anchor members 22 may have a mesh structure, for example closed rhomboidal meshes of the same type as the one represented with reference to the annular elements 20a, 20b, or to simple segments of curve lying in roughly radial planes. Additionally, as discussed above, each anchor member 22 can consist either of a single element or of a plurality of elements (e.g., pairs of anchor members 22 as shown in FIGS. 2-7) that extend in a direction in which they are generally set alongside one another.


The annular elements 20a and 20b and the respective anchor members 22 substantially form the basic structure of the armature 2 of the prosthesis 1, which is designed to ensure positioning and anchorage in situ of the prosthesis 1 itself.


Associated then to the annular elements 20a and 20b are further support members, generically designated by 24 in all of FIGS. 2 to 7, which operate to support the valve sleeve 3 on the armature 2 of the prosthesis 1. In the embodiment represented in FIG. 2, the support members 24 are simply represented by three generally flat bars extending between and connecting the annular members 20a, 20b. As further illustrated, the support members 24 are set at an angular distance apart of about 120°, with each generally located at a position that is approximately centrally intermediate the anchor members 22.


As may be appreciated from a comparative examination of FIGS. 1 and 2, the support members 24 are designed to enable the installation of the valve sleeve 3 in a condition such that the base portion 30 thereof is arranged in general in a position around the annular element 20a of the armature 2, while each of the pleat formations or folds 32 in turn embraces one of the elements or support members 24, while the valve leaflets 3a, 3b and 3c extend in a festoon, each between two adjacent support members 24. The general apertured structure both of the annular element 20a and of the support members 24 (note the particular holes designated by 26) enables fixing of the valve sleeve 3 on the armature 2 by, for example, suturing stitches according to known techniques. In the case where flaps of polymeric materials are used, the flaps can be formed directly on the structure, using techniques such as, for example, dip casting.


In this regard, both the armature 2 and the aforesaid suturing stitches can be advantageously provided with a coating of biocompatible carbon material, which may be applied according to the solutions described in U.S. Pat. Nos. 4,624,822, 4,758,151, 5,084,151, 5,133,845, 5,370,684, 5,387,247, and 5,423,886, the contents of which are hereby incorporated by reference.


The apertured structure of the supporting formations 24, and of the armature 2 in general, means that the armature 2 does not exert any substantial obtrusive effect, preventing, for example, interference in regard to the coronary ostia.



FIG. 3 depicts an alternative embodiment of the armature 2 of the present invention. The variant embodiment represented in FIG. 3 as a whole resembles the embodiment represented in FIG. 2, with the exception that (in the embodiment of FIG. 3) the support members 24 provided for anchorage of the valve sleeve 3 do not extend completely in bridge-like fashion between the two annular parts 20a and 20b. Rather, in the embodiment illustrated in FIG. 3, the support members 24 are projecting elements that extend in cantilever fashion starting from the annular element 20a, and do not reach the annular element 20b. In particular, the lengths of the aforesaid cantilevered support members 24 are determined in such a way as to extend for a length sufficient to enable anchorage of the valve sleeve 3 to the support members 24 at the pleat formations 32. Thus, in one embodiment, the support members 24 do not include any portions other than those portions which operate to support the valve sleeve 3.



FIG. 4 illustrates another embodiment of the armature 2 according to the present invention. As shown, in the embodiment of FIG. 4, like that shown in FIG. 3, the support members 24 project in cantilever fashion from the annular element 20a. As further shown in FIG. 4, in this embodiment, the support members 24 have associated thereto fork-like structures 28. Each fork-like structure 28 has a root portion connected to the annular element 20b and two prongs that extend on either side of the respective support member 24 and then connect up to the annular element 20a on opposite sides with respect to the area in which the support member 24 projects in cantilever fashion from the formation 20a.


As further shown in FIG. 4, in one embodiment, the support members 24 are generally tapered, such that they have widths that decrease gradually moving away from the annular element 20a, that is, in the proximal-to-distal direction with reference to the direction of free flow of the blood through the prosthesis. As will be apparent to those skilled in the art, tapering of the support members 24 may be employed in any of the embodiments illustrated in FIGS. 2 to 4. Similarly, any of the other characteristics of the support members 24 or the anchor members 22, which albeit herein represented are identical to one another in each of the embodiments illustrated, could in actual fact be different from one another. That is, in any embodiment of the valve prosthesis 1, there could coexist, in a single prosthesis, anchor members 22 or support members 24 different from one another, with characteristics drawn from different embodiments amongst the plurality of embodiments illustrated herein.


The solution represented in FIG. 4 generally provides a more rigid anchorage structure as compared to the embodiment of FIG. 3. In the embodiment illustrated in FIG. 4, the fork-like formations 24 effectively fix the axial dimension of the prosthesis 1, which promotes the expansion of the anchor members 22 in the sinuses of Valsalva. At the same time, in the illustrated embodiment of FIG. 4, the support members 24, which operate to facilitate attachment of the valve sleeve 3 to the armature 2, are maintained flexible and of modulatable stiffness.


In the embodiment represented in FIG. 5, the support members 24 are provided in positions corresponding to both of the annular elements 20a, 20b. In this case, however, the support members 24 provided for anchorage of the valve sleeve 3 are reduced to small hooking cantilevers, each provided with an eyelet 26. The eyelets 26 can be used directly for passing and tying the wires that extend from the valve sleeve 30.


Yet another embodiment is shown in FIG. 6, in which the support members 24 are arranged in opposed pairs, with each of the support members 24 within a pair extending in cantilever fashion from one of the annular elements 20a, 20b and being connected by a connecting element 34. In one embodiment, the connecting elements 34 may have a generally filiform (i.e., relatively long and thin) shape, whereby the connecting elements 34 may be made relatively flexible and thus may provide a flexible connection between the support members 24. In one embodiment, the connecting elements 34 may be made from biocompatible metal alloys (e.g., Nitinol) or polymeric materials suitable for applications in the field of implantations (e.g., acetal resins).


As shown, the overall configuration of the embodiment of FIG. 6 generally resembles, from a geometrical standpoint, the embodiment represented in FIG. 2. The difference lies in the fact that, whereas the support members 24 represented in FIG. 2 are as a whole generally stiff (taking into account the intrinsic flexibility of the material that constitutes them), the connecting elements 34 shown in FIG. 6 may have a filiform shape with a relatively high flexibility. The embodiment illustrated in FIG. 6 thus enables the configuration for hooking of the valve sleeve 3 to the armature 2 of the prosthesis to be rendered elastic/flexible and renders the extent of the anchor members 22 independent of that of the support members 24, thus enabling a greater elasticity of design.



FIG. 7 depicts yet another embodiment of the armature 2, which is otherwise similar to the embodiment illustrated in FIG. 6, except that in the embodiment of FIG. 7, the mutually facing pairs of support members 24 are not connected to each other (as by the connecting members 34 in FIG. 6). Instead, in the embodiment represented in FIG. 7, a supporting element 36 extends between and connects each of the support members 24 extending in cantilever fashion from the annular element 20b. As shown, the supporting elements 36 may extend in a generally festoon-like or catenary path between each of the support members 24 attached to the annular part 20b. The supporting elements 36 are configured such that each can support one of the valve leaflets 3a, 3b, or 3c of the valve sleeve 3. The supporting elements 36 may be made of substantially rigid or flexible materials.


In another embodiment (not shown), the supporting elements 36 may be configured to extend from the support members 24 extending in cantilever fashion from the annular element 20a.


As will be readily understood by those skilled in the art, festoon-like or catenary pattern of the supporting elements 36 may be generally configured to match the homologous pattern of the proximal edges of the valve leaflets 3a, 3b and 3c (see FIG. 1), defining the profile of the edge for anchorage of the functional flaps and, possibly, enabling connection by suture of the aforesaid proximal edges of the valve leaflets to the festoon-like supporting elements 36. This enables the use of relatively simple valve sleeves 3, assigning the formation of the profile of the functional flaps of the valves to the supporting elements 36.


The embodiments of the present invention described herein enables, in the final position of implantation, the entire armature 2 of the prosthesis 1, or at least the anchorage parts, to adhere to the native walls of the implantation site, without interfering with the blood flow, which thus remains practically free. Additionally, the armature 2 and anchor members 22 moreover have a generally apertured structure (for example, appropriate slits), which prevents interference with the coronary ostia.


The anchorage portions and the portions of functional support of the armature 2 can constitute either different parts of a single structure or parts that are structurally distinct from one another. The entire armature 2, or at least the anchorage parts (e.g., the anchor members 22), may be made of re-absorbable material, whereas the valve sleeve 3 can be constituted by biological and/or synthetic tissues, which are in part colonizable or re-absorbable.


Alternatively, as discussed above, the armature 2 can contain anchorage formations (e.g., anchor members 22) made at least partially of shape-memory material (e.g., Nitinol), which enable creation or regulation of the anchorage through the control of the memory of the shape-memory material (e.g., controlling its temperature).



FIGS. 8 and 9 illustrate plan and cross-sectional views, respectively, of the prosthesis 1 in its implanted state in an aortic valve replacement, according to an embodiment of the invention. As shown, and as discussed in detail above, the prosthesis 1 can be implanted such that the annular elements 20a and 20b occupy positions proximal and distal, respectively, of the Valsalva sinuses VS, with the flared proximal end of the annular member 20a forming the proximal entrance of the lumen defined by the armature 2 of the prosthesis 1. In the illustrated embodiment, the anchor members 22 can be arranged in three pairs positioned relative to the sinuses of Valsalva such that the radially projecting portion of each of the anchor members 22 projects into the respective sinus of Valsalva and engages the aortic wall therein. As further shown, the anchor members 22 of each pair can be positioned on opposite sides of the coronary ostia CO in the respective sinuses of Valsalva. Additionally, as discussed above and shown in FIGS. 8 and 9, the serpentine or otherwise generally apertured structure of the anchor members 22 substantially avoids interference with the coronary ostia CO. Finally, as can be seen from FIGS. 8 and 9, the valve leaflets 3a, 3b, 3c can be positioned within the lumen for blood flow formed by the annular elements 20a, 20b, with the support members 24 extending into the lumen by a minimal amount.


The armature 2 of the prosthesis 1, according to one embodiment, is manufactured by first cutting a blank part from a tube of a biocompatible metal (e.g., Nitinol, or a cobaltum-chromium alloy) having an outer diameter which is at an intermediate size between the fully radially contracted and the fully expanded device dimensions. For example, the tube may have an outer diameter of between about 8 mm to about 14 mm. In one embodiment, the tube has a diameter of about 10 mm. In one embodiment, the tube wall may vary between about 0.3 mm to about 0.5 mm, depending on the required stiffness required and the size of the prosthesis 1.


In one embodiment, the final dimension and shape of the framework is achieved by a sequence of expansion cycles. A specific heat treatment is applied after each expansion cycle to homogenize and stress relieve the material, which allows the shape and properties of the structure of the armature 2 to be set. Although the number of forming steps may vary among devices, for the geometries described above with respect to the present invention, and using Nitinol for the tube blank, an exemplary number of forming steps is around three. Among these steps, the first two provide the final diameter of the annular elements 20a, 20b. For example, if the fully-expanded diameter for implantation is 23 mm, the final cylindrical shape of the armature 2 can be achieved using a tube blank of about 10 mm in diameter, a first expansion from about 10 mm to about 18 mm, and a second expansion from about 18 mm to about 23 mm. Optionally, the final diameter can be made slightly larger (e.g. about 25 mm in the previous example) in order to oversize the armature 2 with respect to the physiological annulus, thus imparting a radial force to the wall of the annulus at the nominal implant diameter.


The third forming step is aimed to impart the radially extending shape of the anchor members 22 such that they will fit and anchor within the Valsalva sinuses. The corresponding heat treatment, according to one embodiment, includes exposing the deformed armature 2 to a temperature from about 480° C. to about 550° C., for a time ranging from about 5 minutes to about 30 minutes, depending on the desired final transformation temperature. For example, in order to obtain a super-elastic behavior at 37° C. (the normal working condition in human body) the heat treatments subsequent to the two initial expansion steps may be performed at about 480° C. for a time of about 9 minutes, and the final heat treatment (after the third expansion) is performed at about 500° C. for a time of about 9 minutes.


After the forming process is complete, the armature 2 may undergo one or more surface treatments, for example, sandblasting and electropolishing, to provide a sufficiently smooth surface and to remove the shallow defects. The armature 2 may thereafter be finally exposed to a carbon coating process in order to improve its hemocompatibility.


As shown in FIGS. 8-9, for an aortic valve replacement, the final geometrical shape of the armature 2 will generally approximate the physiological shape and dimension of the aortic root, such that the anchor members 22 generally conform to the walls of the respective Valsalva sinuses VS.



FIG. 10 shows a schematic cross sectional view of an implantation site for an aortic valve replacement. Referring to FIG. 10, exemplary proportions of the relevant features at the implantation site for an aortic valve replacement are as follows (assuming the annulus diameter Dimp (implanting diameter) equal to 1):
















Approximate
Approximate



Minimum
Maximum




















Height of Valsalva
0.8
1



sinuses (H):



Max. diameter of
1.3
1.7



Valsalva sinuses



(Dmax):



Distance between
0.3
0.5



Valsalva max.



diameter and



basic annulus



plane (Hmax):



Diameter at the
0.8
1.4



sino-tubular



junction (Dstj):










According to one exemplary embodiment, H is about 0.9, Dmax is about 1.5, Hmax is about 0.35, and Dstj is about 1.2.


The commissural points of the elastic collapsible valve 3 are mounted to the armature 2 (e.g., by attachment to the support members 24) such that the valve leaflets 3a, 3b, and 3c can fold and expand together. The valve 3, including the valve leaflets 3a, 3b, 3c, can be, for example, a glutaraldehyde fixed pericardium valve which has three cusps that open distally to permit unidirectional blood flow.


In one embodiment, the valve member may use two pericardium sheets. The first sheet forms the three moving cusps, the second sheet coats part of the armature 2 surface so that there is no contact between the armature 2 and the valve leaflets avoiding the risk of abrasion due to repeated impact against the metallic material of the armature 2. In addition, this second sheet redistributes the stress applied by blood pressure on the prosthetic leaflets, avoiding the risk of stress concentration.


The two sheets of pericardium may be stitched together flat using suture thread coated with a film of biocompatible material, and then close in a cylindrical shape. The type of stitch used may be varied to accommodate the directional differences in the forces exerted at each point of the suture, to ensure that the stitches themselves don't become the origin of fatigue fracture lines. The two sheets may be stitched together in a flat position so when the leaflets open they recover their original cylindrical configuration, forming a cylindrical duct.


The elastically collapsible valve sleeve 3 can be mounted on the armature 2 by means of a number of suture stitches. Both of the sheets are useful for attaching the valve sleeve 3 to the armature 2 by stitching.


The valve member can use a tissue fixation and shaping of the leaflets 3a, 3b, 3c by means of a fluidic, atraumatic system with chemicals useful for cross-linking and then may be exposed to a detoxification post treatment to increase long-term performance. An additional pericardium sheet corresponding to base portion 30 of the valve sleeve 3 can be positioned in a generally cylindrical fashion around the annular element 20a so as to improve the sealing capability of the prosthesis 1 to the valve annulus.


Various modifications and additions can be made to the exemplary embodiments discussed without departing from the scope of the present invention. Accordingly, the scope of the present invention is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the claims, together with all equivalents thereof.

Claims
  • 1. A cardiac valve prosthesis adapted for implantation at an implantation site of a patient, the implantation site having an annulus, a plurality of Valsalva sinuses, coronary ostia, and a vessel wall distal to the Valsalva sinuses, the prosthesis having a principal axis extending longitudinally therethrough and comprising: an armature adapted for delivery in a radially collapsed configuration and deployment in a radially expanded configuration, the armature defining a lumen for passage of blood flow and comprising: first and second annular elements positioned about the principal axis, the first annular element adapted to engage a wall of the annulus proximal to the Valsalva sinus and the second annular element adapted to engage the vessel wall distal to the Valsalva sinus;a plurality of anchor members extending from the first annular element to the second annular element, each anchor member arching radially outward with respect to the annular elements such that the anchor member is adapted to extend into and generally conform to a respective one of the Valsalva sinuses between the first and second annular elements to enable anchorage of the prosthesis at the implantation site when the cardiac valve prosthesis is deployed at the implantation site with the armature in the radially expanded configuration; anda plurality of valve support members connected to and extending between the first and second annular elements and oriented generally parallel to the principal axis of the prosthesis, wherein each of the valve support members and each of the anchor members are angularly spaced from one another around the principal axis; anda set of prosthetic valve leaflets coupled to the valve support members.
  • 2. The prosthesis of claim 1 wherein the armature comprises three anchor members angularly distributed around the prosthesis such that each anchor member can extend into a respective Valsalva sinus.
  • 3. The prosthesis of claim 2 wherein each of the anchor members has a generally serpentine shape.
  • 4. The prosthesis of claim 2 wherein each of the annular elements is made from a shape memory material.
  • 5. The prosthesis of claim 2 wherein the anchor members are made from a shape memory material.
  • 6. The prosthesis of claim 2 wherein the anchor members are made substantially from a re-absorbable material.
  • 7. The prosthesis of claim 1 wherein each of the annular elements has a mesh structure.
  • 8. The prosthesis of claim 7 wherein each of the annular elements has a rhomboidal-mesh structure.
  • 9. The prosthesis of claim 1 wherein at least one of the annular elements is flared outward at a proximal end.
  • 10. The prosthesis of claim 1 wherein at least one of the support members comprises a plurality of apertures.
  • 11. The prosthesis of claim 1 wherein the at least one of the support members has a tapered pattern.
  • 12. The prosthesis of claim 11 wherein the at least one of the support members has a width that decreases in the proximal-to-distal direction.
  • 13. The prosthesis of claim 1 wherein the valve leaflets are made substantially of materials selected from the group consisting of biological tissues, colonizable tissues, and re-absorbable tissues.
  • 14. A cardiac valve prosthesis for implantation at an implantation site of a patient, the prosthesis having a principal axis extending longitudinally therethrough and comprising: an anchoring structure having a collapsed configuration and an expanded configuration, the anchoring structure defining a lumen;a valve coupled to the anchoring structure and configured such that in the expanded configuration, the valve permits blood flow through the lumen in a first direction and substantially prevents blood flow through the lumen in a second direction opposite the first direction,wherein the anchoring structure includes a first generally cylindrical portion positioned about the principal axis adapted to engage an annular wall of the implantation site proximal to a Valsalva sinus, a second generally cylindrical portion positioned about the principal axis adapted to engage a vessel wall distal to the Valsalva sinus, Valsalva sinus anchoring means for anchoring the prosthesis at the implantation site, the Valsalva sinus anchoring means connected to and extending between the first and second generally cylindrical portions and arching radially outwardly with respect to the first and second generally cylindrical portions for generally conforming to and engaging a wall of the Valsalva sinus of the implantation site between the first generally cylindrical portion and the second generally cylindrical portion, and a plurality of valve support members connected to and extending between the first and second generally cylindrical portions in a direction generally parallel to the principal axis of the prosthesis, wherein each of the valve support members and the Valsalva sinus anchoring means are angularly spaced from one another about the principal axis of the prosthesis.
  • 15. The prosthesis of claim 14 wherein the first or second generally cylindrical portion has a mesh structure.
  • 16. The prosthesis of claim 15 wherein the first or second generally cylindrical portion has a rhomboidal-mesh structure.
  • 17. The prosthesis of claim 14 wherein the first or second generally cylindrical portion is made from a shape memory material.
  • 18. The prosthesis of claim 14 wherein the means for anchoring are made from a shape memory material.
  • 19. A method for percutaneous implantation of a cardiac valve prosthesis at an implantation site having an annulus and a Valsalva sinus having a wall and a coronary ostia, the prosthesis having a principal axis extending longitudinally therethrough, the method comprising deploying the prosthesis from a delivery catheter such that a first generally cylindrical portion of the prosthesis positioned about the principal axis engages a wall of the annulus, a second generally cylindrical second portion of the prosthesis positioned about the principal axis engages a vessel wall distal to the Valsalva sinus, a Valsalva sinus anchor portion of the prosthesis expands to a size and shape arching radially outwardly and conforming to the wall of the Valsalva sinus between the first and second generally cylindrical portions, and a plurality of valve leaflet support members extend between the first and second generally cylindrical portions in a direction generally parallel to the principal axis of the prosthesis, wherein each of the valve leaflet support members and the Valsalva sinus anchor portion are angularly spaced from one another about the principal axis of the prosthesis.
Priority Claims (1)
Number Date Country Kind
TO2005A0074 Feb 2005 IT national
US Referenced Citations (209)
Number Name Date Kind
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3997923 Possis Dec 1976 A
4056854 Boretos et al. Nov 1977 A
4086665 Poirier May 1978 A
4451936 Carpentier et al. Jun 1984 A
4477930 Totten et al. Oct 1984 A
4506394 Bedard Mar 1985 A
4692164 Dzemeshkevich et al. Sep 1987 A
4758151 Arru et al. Jul 1988 A
4777951 Cribier et al. Oct 1988 A
4994077 Dobben Feb 1991 A
5084151 Vallana et al. Jan 1992 A
5123919 Sauter et al. Jun 1992 A
5133845 Vallana et al. Jul 1992 A
5139515 Robicsek Aug 1992 A
5314468 Martinez et al. May 1994 A
5332402 Teitelbaum Jul 1994 A
5370685 Stevens Dec 1994 A
5387247 Vallana et al. Feb 1995 A
5397351 Pavcnik et al. Mar 1995 A
5411552 Andersen et al. May 1995 A
5423886 Arru et al. Jun 1995 A
5545214 Stevens Aug 1996 A
5545215 Duran Aug 1996 A
5554185 Block et al. Sep 1996 A
5712953 Langs Jan 1998 A
5716417 Girard et al. Feb 1998 A
5824037 Fogarty et al. Oct 1998 A
5824064 Taheri Oct 1998 A
5840081 Andersen et al. Nov 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5876436 Vanney et al. Mar 1999 A
5891195 Klostermeyer et al. Apr 1999 A
5925063 Khosravi Jul 1999 A
5954766 Zadno-Azizi et al. Sep 1999 A
5957949 Leonhardt et al. Sep 1999 A
5980570 Simpson Nov 1999 A
6162245 Jayaraman Dec 2000 A
6168614 Andersen et al. Jan 2001 B1
6197143 Bodnar Mar 2001 B1
6245102 Jayaraman Jun 2001 B1
6270526 Cox Aug 2001 B1
6299638 Sauter Oct 2001 B1
6309417 Spence et al. Oct 2001 B1
6312462 McDermott et al. Nov 2001 B1
6352554 De Paulis Mar 2002 B2
6402780 Williamson, IV et al. Jun 2002 B2
6425916 Garrison et al. Jul 2002 B1
6440164 DeMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6482228 Norred Nov 2002 B1
6494909 Greenhalgh Dec 2002 B2
6544285 Thubrikar et al. Apr 2003 B1
6569196 Vesely May 2003 B1
6582462 Andersen et al. Jun 2003 B1
6652578 Bailey et al. Nov 2003 B2
6656219 Wiktor Dec 2003 B1
6685739 DiMatteo et al. Feb 2004 B2
6730118 Spenser et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6790230 Beyersdorf et al. Sep 2004 B2
6805711 Quijano et al. Oct 2004 B2
6830584 Seguin Dec 2004 B1
6830585 Artof et al. Dec 2004 B1
6875231 Anduiza et al. Apr 2005 B2
6929653 Strecter Aug 2005 B2
7018404 Holmberg et al. Mar 2006 B2
7125418 Duran et al. Oct 2006 B2
7175656 Khairkhahan Feb 2007 B2
7186265 Sharkawy et al. Mar 2007 B2
7211107 Bruckheime May 2007 B2
7252682 Seguin Aug 2007 B2
7255706 Rosengart Aug 2007 B2
7261732 Justino Aug 2007 B2
7276078 Spenser et al. Oct 2007 B2
7329278 Seguin et al. Feb 2008 B2
7329279 Haug et al. Feb 2008 B2
7347869 Hojeibane et al. Mar 2008 B2
7351256 Hojeibane et al. Apr 2008 B2
7377938 Sarac et al. May 2008 B2
7377941 Rhee et al. May 2008 B2
7381218 Schreck Jun 2008 B2
7393360 Spenser et al. Jul 2008 B2
7534259 Lashinski et al. May 2009 B2
7556645 Lashinski et al. Jul 2009 B2
7569071 Haverkost et al. Aug 2009 B2
7578843 Shu Aug 2009 B2
7585321 Cribier Sep 2009 B2
7591848 Allen Sep 2009 B2
7618446 Andersen et al. Nov 2009 B2
7618447 Case et al. Nov 2009 B2
7708775 Rowe et al. May 2010 B2
20010002445 Vesely May 2001 A1
20010007956 Letac et al. Jul 2001 A1
20010010017 Letac et al. Jul 2001 A1
20010039450 Pavcnik et al. Nov 2001 A1
20020042651 Liddicoat et al. Apr 2002 A1
20020058994 Hill et al. May 2002 A1
20020058995 Stevens May 2002 A1
20020123802 Snyders Sep 2002 A1
20020128702 Menz et al. Sep 2002 A1
20020133226 Marquez et al. Sep 2002 A1
20020138138 Yang Sep 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020198594 Schreck Dec 2002 A1
20030014104 Cribier Jan 2003 A1
20030023300 Bailey et al. Jan 2003 A1
20030023303 Palmaz et al. Jan 2003 A1
20030036795 Andersen et al. Feb 2003 A1
20030055495 Pease et al. Mar 2003 A1
20030109924 Cribier Jun 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030149476 Damm et al. Aug 2003 A1
20030153974 Spenser et al. Aug 2003 A1
20030163194 Quijano et al. Aug 2003 A1
20030191528 Quijano et al. Oct 2003 A1
20030208261 Thorpe et al. Nov 2003 A1
20040034407 Sherry Feb 2004 A1
20040034411 Quijano et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040055606 Hendricksen et al. Mar 2004 A1
20040078072 Tu et al. Apr 2004 A1
20040078074 Anderson et al. Apr 2004 A1
20040093060 Seguin et al. May 2004 A1
20040093070 Hojeibane et al. May 2004 A1
20040093075 Kuehne May 2004 A1
20040106976 Bailey et al. Jun 2004 A1
20040260389 Case et al. Dec 2004 A1
20050010285 Lambrecht et al. Jan 2005 A1
20050033398 Seguin Feb 2005 A1
20050075584 Cali Apr 2005 A1
20050075712 Biancucci et al. Apr 2005 A1
20050075713 Biancucci et al. Apr 2005 A1
20050075717 Nguyen et al. Apr 2005 A1
20050075718 Nguyen et al. Apr 2005 A1
20050075719 Bergheim Apr 2005 A1
20050075720 Nguyen et al. Apr 2005 A1
20050075724 Svanidze et al. Apr 2005 A1
20050075726 Svanidze et al. Apr 2005 A1
20050075728 Nguyen et al. Apr 2005 A1
20050075729 Nguyen et al. Apr 2005 A1
20050075730 Myers et al. Apr 2005 A1
20050075731 Artof et al. Apr 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137687 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137692 Haug et al. Jun 2005 A1
20050137693 Haug et al. Jun 2005 A1
20050137694 Haug et al. Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050137699 Salahieh et al. Jun 2005 A1
20050137701 Salahieh et al. Jun 2005 A1
20050137702 Haug et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050222675 Sauter Oct 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20060085060 Campbell Apr 2006 A1
20060178740 Stacchino et al. Aug 2006 A1
20060190017 Cyr et al. Aug 2006 A1
20060195184 Lane et al. Aug 2006 A1
20060259137 Artof et al. Nov 2006 A1
20070032850 Ruiz et al. Feb 2007 A1
20070093887 Case et al. Apr 2007 A1
20070093890 Eliasen et al. Apr 2007 A1
20070100432 Case et al. May 2007 A1
20070100435 Case et al. May 2007 A1
20070100440 Figulla et al. May 2007 A1
20070106372 Osborne et al. May 2007 A1
20070118209 Strecker May 2007 A1
20070118215 Moaddeb May 2007 A1
20070168024 Khairkhahan Jul 2007 A1
20070185513 Woolfson et al. Aug 2007 A1
20070233228 Eberhardt et al. Oct 2007 A1
20070237802 McKay et al. Oct 2007 A1
20070239265 Birdsall et al. Oct 2007 A1
20070239273 Allen Oct 2007 A1
20070244544 Birdsall et al. Oct 2007 A1
20070260305 Drews et al. Nov 2007 A1
20070265701 Gurskis et al. Nov 2007 A1
20070270944 Bergheim et al. Nov 2007 A1
20070293942 Mirzaee Dec 2007 A1
20080065204 Macoviak et al. Mar 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080082164 Friedman Apr 2008 A1
20080097595 Gabbay Apr 2008 A1
20080125859 Salahieh et al. May 2008 A1
20080133033 Wolff et al. Jun 2008 A1
20080188880 Fischer et al. Aug 2008 A1
20080228263 Ryan Sep 2008 A1
20090157175 Benichou et al. Jun 2009 A1
20090164006 Seguin et al. Jun 2009 A1
20090171456 Kveen et al. Jul 2009 A1
20090209955 Forster et al. Aug 2009 A1
20090210052 Forster et al. Aug 2009 A1
20090222082 Lock et al. Sep 2009 A1
20090222084 Friedman Sep 2009 A1
20090254165 Tabor et al. Oct 2009 A1
Foreign Referenced Citations (45)
Number Date Country
195 46 692 Jun 1997 DE
198 57 887 Jul 2000 DE
0 133 420 Feb 1988 EP
0 155 245 May 1990 EP
0 592 410 Oct 1995 EP
0 850 607 Jul 1998 EP
1 057 460 Dec 2000 EP
1 088 529 Apr 2001 EP
1 259 194 Feb 2005 EP
1 214 020 Mar 2005 EP
2 055 266 May 2005 EP
1 570 809 Sep 2005 EP
1 014 896 Nov 2005 EP
1 603 493 Dec 2005 EP
1 600 127 Nov 2006 EP
1 143 882 May 2007 EP
1 330 213 Mar 2009 EP
1 370 201 Sep 2009 EP
2 133 039 Dec 2009 EP
1 017 275 Aug 2002 NL
WO 9724989 Jul 1997 WO
WO 9817202 Apr 1998 WO
WO 9829057 Jul 1998 WO
WO 9913802 Mar 1999 WO
WO 9956665 Nov 1999 WO
WO 0041852 Jul 2000 WO
WO 0047139 Aug 2000 WO
WO 0062714 Oct 2000 WO
WO 0062716 Oct 2000 WO
WO 0121107 Mar 2001 WO
WO 0162189 Aug 2001 WO
WO 0164137 Sep 2001 WO
WO 0176510 Oct 2001 WO
WO 0241789 May 2002 WO
WO 02047575 Aug 2002 WO
WO 02078348 Oct 2002 WO
WO 03003943 Jan 2003 WO
WO 03003949 Jan 2003 WO
WO 03094797 Nov 2003 WO
WO 2004082527 Sep 2004 WO
WO 2004091455 Oct 2004 WO
WO 2005046528 May 2005 WO
WO 2006044679 Apr 2006 WO
WO 2006086135 Aug 2006 WO
WO 2009029199 Mar 2009 WO
Related Publications (1)
Number Date Country
20060178740 A1 Aug 2006 US